Events

Loading Events

« All Events

  • This event has passed.

Safety Pharmacology Society 2017 Annual Meeting

September 24, 2017 - September 27, 2017

Event Navigation

Highlights of the Annual Meeting

  • A dynamic forum for best practice sharing within industry, CRO’s, academics and regulators
  • Scientific Sessions organized by SPS Members
  • Sessions on some of the hottest topics in safety pharmacology related research
  • 6 CE Courses taught by experts in the field
  • Plenary Keynote Speakers by a key opinion leaders
  • Exhibit hall offering access to industry vendors
  • Poster sessions featuring cutting-edge research
  • Networking opportunities with a global community of scientists from regulatory, industry, and academia
  • Award opportunities to bring together Student and Jr. Investigators with seasoned scientists, while sharing their research
  • Exhibitor Sponsored Sessions by leading technology and service providers showcasing their new offerings and research

Presentation

CDI Exhibitor Tutorial: Human-based Seizurogenic Assays: Using iPSC-derived Glutamatergic Neurons to Assess Drug-induced Changes in Network Activity

Tuesday, September 26 | 7:00 – 8:00 am | Salon 5

Cyprotex – an Evotec Company and Cellular Dynamics International – a FUJIFILM company

Abstract: iCell Glutamatergic Neurons are iPSC-derived human excitatory neurons that form spontaneously bursting networks modulated by pro-convulsant and neuroactive molecules, thus adding a new dimension to the toxicologist’s toolbox. This workshop will illustrate the attributes of these neurons, provide case studies highlighting their use, and illustrate potential analyses for pro-seizurogenic investigations. Human-based seizurogenic assays: Using iPSC-derived glutamatergic neurons to assess drug-induced changes in network activity


Continuing Education Course

PM2: Building on the Classics: The Emerging Role of Stem Cell-Based Techniques in Safety Pharmacology Assessments

Sunday, September 24 | 2:00 – 6:00 pm

Co-Chairs: Blake Anson1 and Amy Pointon2

  1. Cellular Dynamics International – a FUJIFILM company
  2. AstraZeneca PLC

Description: Human stem cell technology is bringing new tools to drug discovery, toxicity testing, and safety pharmacology. This CE course will build on traditional safety pharmacology topics to cover how this technology is being developed for use as a safety tool as well as a therapeutic. Lectures will cover the use of stem cell derived cardiomyocytes and neurons in simple and complex culture systems to understand and predict traditional drug-induced effects on cardiomyocyte electrophysiology, contractility, and neuronal seizureogenic behavior. The course will then expand to include a discussion on stem cell-based regenerative medicine applications and related potential safety considerations. Where appropriate, speakers will compare and contrast stem cell models with more traditional models to highlight the potential advantages and limitations. Attendees will come away from the course with a practical understanding of how and when to apply current stem cell-based models, the limitations of such models, and ultimately how the technology is evolving in both the therapeutic and safety arenas.


Joint Workshops

Functional Enhancement of Human iPSC-derived Cardiomyocytes Enabling Assessment of Inotropic Compounds and Improved Prediction of Compound Risk

Monday, September 25,  6-7 pm |  Maritim Hotel, Room A

ACEA Biosciences Inc. and Cellular Dynamics International – a FUJIFILM company

Description: Human iPSC-derived cardiomyocytes (hiPSC-CMs) display a repertoire of ionic currents and channels which makes them a relevant model for safety/toxicity assessment including screening of pro-arrhythmic compounds. However, the contractile apparatus and calcium handling mechanisms of hiPSC-CM is continuing to develop  and therefore may not be optimal for assessment of compounds which modulate the force of contraction.  In order to enhance the ability of hiPSC-CM to respond to compounds that modulate the force of contraction, the xCELLigence RTCA CardioECR system (ACEA Biosciences, Inc) was used to electrically pace iCell Cardiomyocytes2 (Cellular Dynamics International – a FUJIFILM company) for up to 3 weeks. The contraction and electrophysiology of iCell Cardiomyocytes2 were recorded using simultaneous measurement of impedance and field potential recording, respectively. Our data clearly demonstrate that electrical pacing leads to positive force-frequency relationship, improved contraction of paced iCell Cardiomyocytes2 by positive inotropic compounds and optimal localization of key proteins involved in calcium handling. In summary, our data shows that electrical pacing leads to enhanced functionality of iCell Cardiomyocytes2 and increases its range of applications for both drug discovery and safety studies.


Oral Communication

Multiparametric Assessment of Networked Electrical Activity Using Induced Pluripotent Stem Cell-derived Glutamatergic Neurons

Poster 0099 | Oral Communication Nominee | Presenter: TK Feaster, PhD.

Kim, KH, Carlson, C, Kannemeier, C, Feaster, TK, Swanson, B, Schlesinger S, Anson, B and Mangan, K

Cellular Dynamics International – a FUJIFILM Company


Poster Presentations

Details

Start:
September 24, 2017
End:
September 27, 2017
Website:
https://www.safetypharmacology.org/AM2017/index.asp

Organizer

Safety Pharmacology Society
Website:
http://www.safetypharmacology.org/index.asp